beta-amino acid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	beta-amino acid	go back to main search page
Accession:	CHEBI:33706	browse the term
Definition:	A non-proteinogenic amino acid in which the amino group is located on the carbon atom at the position beta to the carboxy group.
Synonyms:	related_synonym:	beta-amino acids

show annotations for term's descendants Sort by:
Rat (231 ) Mouse (237 ) Human (236 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (0 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (231)

(R)-pantothenic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

atonal bHLH transcription factor 8

increases expression

ISO

Pantothenic Acid results in increased expression of ATOH8 mRNA

NCBI chr 4:105,818,203...105,850,379
Ensembl chr 4:105,818,203...105,850,379

G

cell death-inducing DFFA-like effector a

multiple interactions

ISO

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA

NCBI chr18:63,164,817...63,190,384
Ensembl chr18:63,164,099...63,190,382

G

cell death-inducing DFFA-like effector c

multiple interactions

ISO

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806

G

collagen type II alpha 1 chain

multiple interactions

EXP

[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

ISO

Pantothenic Acid results in increased expression of CYP1B1 mRNA

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

family with sequence similarity 43, member A

increases expression

ISO

Pantothenic Acid results in increased expression of FAM43A mRNA

NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297

G

fucosyltransferase 7

decreases expression

ISO

Pantothenic Acid results in decreased expression of FUT7 mRNA

NCBI chr 3:28,635,913...28,640,407
Ensembl chr 3:28,637,107...28,641,388

G

heme oxygenase 1

increases expression

ISO

Pantothenic Acid results in increased expression of HMOX1 mRNA; Pantothenic Acid results in increased expression of HMOX1 protein

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock protein family B (small) member 7

increases expression

ISO

Pantothenic Acid results in increased expression of HSPB7 mRNA

NCBI chr 5:159,010,759...159,014,245
Ensembl chr 5:159,010,629...159,014,243

G

inhibitor of DNA binding 1

increases expression

ISO

Pantothenic Acid results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

inhibitor of DNA binding 3

increases expression

ISO

Pantothenic Acid results in increased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856

G

isocitrate dehydrogenase (NADP(+)) 2

increases abundance
multiple interactions

ISO

IDH2 protein mutant form results in increased abundance of Pantothenic Acid
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Pantothenic Acid]

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

interleukin 6

increases expression

ISO

Pantothenic Acid results in increased expression of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

ISO

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

leptin receptor

affects abundance

ISO

LEPR affects the abundance of Pantothenic Acid

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215

G

membrane associated ring-CH-type finger 2

increases expression

ISO

Pantothenic Acid results in increased expression of MARCHF2 mRNA

NCBI chr 7:15,183,931...15,209,988
Ensembl chr 7:15,183,925...15,202,002

G

mitochondrial transcription rescue factor 1

increases expression

ISO

Pantothenic Acid results in increased expression of MTRES1 mRNA

NCBI chr20:48,604,479...48,622,364
Ensembl chr20:48,604,372...48,622,014

G

MYB proto-oncogene, transcription factor

multiple interactions

ISO

Pantothenic Acid inhibits the reaction [Valproic Acid results in decreased expression of MYB protein]

NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547

G

MYCN proto-oncogene, bHLH transcription factor

increases expression

ISO

Pantothenic Acid results in increased expression of MYCN mRNA

NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508

G

NHL repeat containing E3 ubiquitin protein ligase 1

increases expression

ISO

Pantothenic Acid results in increased expression of NHLRC1 mRNA

NCBI chr17:17,880,570...17,883,411
Ensembl chr17:17,880,365...17,883,620

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

ISO

[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

neuronal regeneration related protein

increases expression

ISO

Pantothenic Acid results in increased expression of NREP mRNA

NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742

G

Pim-1 proto-oncogene, serine/threonine kinase

multiple interactions

ISO

Pantothenic Acid inhibits the reaction [Valproic Acid results in decreased expression of PIM1 protein]

NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764

G

POU class 3 homeobox 4

increases expression

ISO

Pantothenic Acid results in increased expression of POU3F4 mRNA

NCBI chr X:79,974,808...79,976,085
Ensembl chr X:79,974,627...79,987,326

G

protein tyrosine phosphatase, receptor type, C-associated protein

increases expression

ISO

Pantothenic Acid results in increased expression of PTPRCAP mRNA

NCBI chr 1:210,878,593...210,880,752
Ensembl chr 1:210,878,573...210,881,753

G

succinate dehydrogenase complex flavoprotein subunit A

multiple interactions

ISO

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein

NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:30,764,590...30,790,121

G

SLC51 subunit beta

increases expression

ISO

Pantothenic Acid results in increased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier family 5 member 6

increases transport
multiple interactions

EXP
ISO

SLC5A6 results in increased transport of Pantothenic Acid
Sodium affects the reaction [SLC5A6 results in increased transport of Pantothenic Acid]
Thioctic Acid inhibits the reaction [SLC5A6 results in increased transport of Pantothenic Acid]

PMID:9516450 PMID:10329687

NCBI chr 6:31,039,865...31,051,671
Ensembl chr 6:31,040,017...31,051,670

G

SRY-box transcription factor 2

decreases expression

ISO

Pantothenic Acid results in decreased expression of SOX2 mRNA

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

transferrin

multiple interactions

ISO

[acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of CIDEA mRNA; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [acetyl methyl tetramethyl tetralin co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in decreased expression of SDHA protein; [quinoxyfen co-treated with Biotin co-treated with Pantothenic Acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Thyroxine co-treated with TF protein] results in increased expression of CIDEC mRNA

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

transmembrane protein 18

increases expression

ISO

Pantothenic Acid results in increased expression of TMEM18 mRNA

NCBI chr 6:52,934,419...52,941,868
Ensembl chr 6:52,934,419...52,941,866

G

zinc finger protein 575

decreases expression

ISO

Pantothenic Acid results in decreased expression of ZNF575 mRNA

NCBI chr 1:89,302,927...89,305,087
Ensembl chr 1:89,302,904...89,305,187

3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

ISO

Nialamide results in decreased activity of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

solute carrier family 47 member 1

multiple interactions

ISO

Nialamide inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096

G

solute carrier family 47 member 2

multiple interactions

ISO

Nialamide inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr10:46,490,262...46,532,954
Ensembl chr10:46,489,831...46,533,425

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

allograft inflammatory factor 1

decreases expression

ISO

Dabigatran results in decreased expression of AIF1 protein

NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339

G

aldehyde dehydrogenase 1 family, member A2

decreases expression

ISO

Dabigatran results in decreased expression of ALDH1A2 mRNA

NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

ISO

Dabigatran results in decreased expression of EYA1 mRNA

NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614

G

coagulation factor II, thrombin

decreases activity

ISO

Dabigatran results in decreased activity of F2 protein

PMID:17911567 PMID:25138021

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

fibrinogen alpha chain

multiple interactions

ISO

Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577

G

fibrinogen beta chain

multiple interactions

ISO

Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibroblast growth factor 8

increases expression

ISO

Dabigatran results in increased expression of FGF8 mRNA

NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605

G

fibrinogen gamma chain

multiple interactions

ISO

Dabigatran inhibits the reaction [Dietary Fats results in increased cleavage of [FGA protein binds to FGB protein binds to FGG protein]]

NCBI chr 2:170,652,929...170,660,372
Ensembl chr 2:170,652,234...170,661,170

G

forkhead box C2

decreases expression

ISO

Dabigatran results in decreased expression of FOXC2 mRNA

NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977

G

glial cell derived neurotrophic factor

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in decreased expression of GDNF mRNA]

NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240

G

glial fibrillary acidic protein

decreases expression

ISO

Dabigatran results in decreased expression of GFAP protein

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

homeo box B9

increases expression

ISO

Dabigatran results in increased expression of HOXB9 mRNA

NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872

G

mesenchyme homeobox 1

decreases expression

ISO

Dabigatran results in decreased expression of MEOX1 mRNA

NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976

G

MER proto-oncogene, tyrosine kinase

increases expression

ISO

Dabigatran results in increased expression of MERTK mRNA

NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192

G

neurogenin 2

increases expression

ISO

Dabigatran results in increased expression of NEUROG2 mRNA

NCBI chr 2:218,767,205...218,769,772
Ensembl chr 2:218,765,949...218,769,784

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in decreased expression of NR4A2 mRNA]

NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769

G

oligodendrocyte transcription factor 3

increases expression

ISO

Dabigatran results in increased expression of OLIG3 mRNA

NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274

G

paired box 3

decreases expression

ISO

Dabigatran results in decreased expression of PAX3 mRNA

NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141

G

paired box 6

increases expression

ISO

Dabigatran results in increased expression of PAX6 mRNA

NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763

G

proteolipid protein 1

increases expression

ISO

Dabigatran results in increased expression of PLP1 mRNA

NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314

G

REST corepressor 2

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in decreased expression of RCOR2 mRNA]

NCBI chr 1:213,882,585...213,890,022
Ensembl chr 1:213,878,519...213,890,022

G

ret proto-oncogene

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in decreased expression of RET protein]

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

solute carrier family 18 member A2

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA]

NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231

G

synuclein alpha

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in increased expression of SNCA mRNA]

NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:91,026,474...91,126,315

G

transcription factor 15

decreases expression

ISO

Dabigatran results in decreased expression of TCF15 mRNA

NCBI chr 3:161,099,301...161,105,083
Ensembl chr 3:161,099,301...161,105,083

G

tyrosine hydroxylase

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in decreased expression of TH mRNA]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

G

tumor necrosis factor

multiple interactions

EXP

Dabigatran inhibits the reaction [Rotenone results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

UNC homeobox

decreases expression

ISO

Dabigatran results in decreased expression of UNCX mRNA

NCBI chr12:20,206,604...20,211,125
Ensembl chr12:20,206,609...20,211,125

methylphenidate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 1a

increases expression

EXP

Methylphenidate results in increased expression of ADAM1 mRNA

NCBI chr12:40,674,460...40,680,988
Ensembl chr12:40,676,918...40,684,619

G

adrenoceptor alpha 1B

increases expression

EXP

Methylphenidate results in increased expression of ADRA1B mRNA

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

ATP/GTP binding carboxypeptidase 1

increases expression

ISO

Methylphenidate results in increased expression of AGTPBP1 mRNA

NCBI chr17:5,092,108...5,244,414
Ensembl chr17:5,126,146...5,244,420

G

aldo-keto reductase family 1 member B1

decreases expression

ISO

Methylphenidate results in decreased expression of AKR1B1 mRNA

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

adaptor related protein complex 2 subunit beta 1

increases expression

ISO

Methylphenidate results in increased expression of AP2B1 mRNA

NCBI chr10:68,596,925...68,702,547
Ensembl chr10:68,597,093...68,702,539

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1

decreases expression

ISO

Methylphenidate results in decreased expression of ARAP1 mRNA

NCBI chr 1:165,160,701...165,226,219
Ensembl chr 1:165,160,678...165,226,218

G

activity-regulated cytoskeleton-associated protein

affects expression

EXP

Methylphenidate affects the expression of ARC mRNA

NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:108,444,692...108,451,220

G

ariadne RBR E3 ubiquitin protein ligase 2

decreases expression

ISO

Methylphenidate results in decreased expression of ARIH2 mRNA

NCBI chr 8:118,175,267...118,234,425
Ensembl chr 8:118,175,267...118,234,284

G

armadillo repeat containing 9

decreases expression

ISO

Methylphenidate results in decreased expression of ARMC9 mRNA

NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589

G

autophagy related 5

increases expression

EXP

Methylphenidate results in increased expression of ATG5 mRNA

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

beta-1,4-galactosyltransferase 4

decreases expression

ISO

Methylphenidate results in decreased expression of B4GALT4 mRNA

NCBI chr11:75,501,358...75,527,291
Ensembl chr11:75,501,366...75,527,177

G

BCL2 associated X, apoptosis regulator

increases expression

EXP

Methylphenidate results in increased expression of BAX mRNA

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

Bcl-2 binding component 3

increases expression

EXP

Methylphenidate results in increased expression of BBC3 mRNA

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666

G

BCL9, transcription coactivator

decreases expression

ISO

Methylphenidate results in decreased expression of BCL9 mRNA

NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:187,449,425...187,475,241

G

brain-derived neurotrophic factor

affects expression
decreases expression
multiple interactions

EXP
ISO

Methylphenidate affects the expression of BDNF mRNA
Methylphenidate results in decreased expression of BDNF mRNA
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]

PMID:19222557 PMID:22470460 PMID:24394491

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

beclin 1

increases expression

EXP
ISO

Methylphenidate results in increased expression of BECN1 mRNA

PMID:32746681 PMID:32748667

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

complement C2

increases expression

ISO

Methylphenidate results in increased expression of C2 mRNA

NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,955,776...3,981,740

G

caldesmon 1

increases expression

ISO

Methylphenidate results in increased expression of CALD1 mRNA

NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085

G

caspase 3

increases expression
multiple interactions

EXP
ISO

Methylphenidate results in increased expression of CASP3 mRNA
Methylphenidate results in increased expression of and results in increased activity of CASP3 protein

PMID:32746681 PMID:32748667

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases expression

EXP

Methylphenidate results in increased expression of CASP8 mRNA

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions

ISO

Methylphenidate results in increased expression of and results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

catalase

increases activity
decreases activity

EXP
ISO

Methylphenidate results in increased activity of CAT protein
Methylphenidate results in decreased activity of CAT protein

PMID:32746681 PMID:32748667

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

carbonyl reductase 3

increases expression

ISO

Methylphenidate results in increased expression of CBR3 mRNA

NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558

G

coiled-coil domain containing 166

decreases expression

ISO

Methylphenidate results in decreased expression of CCDC166 mRNA

NCBI chr 7:109,574,271...109,576,074
Ensembl chr 7:109,574,273...109,576,074

G

coiled-coil domain containing 91

decreases expression

ISO

Methylphenidate results in decreased expression of CCDC91 mRNA

NCBI chr 4:182,132,931...182,304,948
Ensembl chr 4:182,132,942...182,304,948

G

cyclin-dependent kinase 5 regulatory subunit 1

increases expression

ISO

Methylphenidate results in increased expression of CDK5R1 mRNA

NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272

G

cyclin-dependent kinase inhibitor 1A

increases expression

EXP

Methylphenidate results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

carboxylesterase 1D

multiple interactions
increases hydrolysis
increases metabolic processing

ISO

[CES1 protein results in increased hydrolysis of Methylphenidate] which results in increased chemical synthesis of ritalinic acid; Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; CES1 gene mutant form results in decreased metabolism of and results in increased abundance of Methylphenidate; Fluoxetine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Perphenazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]; Thioridazine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]
aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]
CES1 protein results in increased metabolism of Methylphenidate

PMID:15082749 PMID:18485328 PMID:20097249 PMID:25445008

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

chromodomain helicase DNA binding protein 2

increases expression

ISO

Methylphenidate results in increased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335

G

chromogranin A

decreases expression

ISO

Methylphenidate results in decreased expression of CHGA mRNA

NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237

G

chitinase domain containing 1

decreases expression

ISO

Methylphenidate results in decreased expression of CHID1 mRNA

NCBI chr 1:206,024,059...206,059,259
Ensembl chr 1:205,998,801...206,059,227

G

cholinergic receptor nicotinic alpha 6 subunit

decreases expression

ISO

Methylphenidate results in decreased expression of CHRNA6 mRNA

NCBI chr16:71,400,615...71,407,315
Ensembl chr16:71,400,615...71,407,315

G

carbohydrate sulfotransferase 8

decreases expression

ISO

Methylphenidate results in decreased expression of CHST8 mRNA

NCBI chr 1:96,431,144...96,572,880
Ensembl chr 1:96,431,145...96,572,880

G

caseinolytic mitochondrial matrix peptidase chaperone subunit X

increases expression

ISO

Methylphenidate results in increased expression of CLPX mRNA

NCBI chr 8:74,700,602...74,740,244
Ensembl chr 8:74,700,662...74,744,762

G

cyclin and CBS domain divalent metal cation transport mediator 1

increases expression

ISO

Methylphenidate results in increased expression of CNNM1 mRNA

NCBI chr 1:252,245,377...252,304,205
Ensembl chr 1:252,245,623...252,304,205

G

CCR4-NOT transcription complex, subunit 6-like

decreases expression

ISO

Methylphenidate results in decreased expression of CNOT6L mRNA

NCBI chr14:13,714,475...13,806,481
Ensembl chr14:13,714,475...13,806,481

G

cannabinoid receptor 1

increases expression

ISO

Methylphenidate results in increased expression of CNR1 mRNA

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

contactin 3

increases expression

EXP

Methylphenidate results in increased expression of CNTN3 mRNA

NCBI chr 4:136,397,575...136,770,765
Ensembl chr 4:136,398,572...136,770,717

G

contactin 4

increases expression

EXP

Methylphenidate results in increased expression of CNTN4 mRNA

NCBI chr 4:140,180,696...141,177,771
Ensembl chr 4:140,596,284...141,177,766

G

catechol-O-methyltransferase domain containing 1

decreases expression

ISO

Methylphenidate results in decreased expression of COMTD1 mRNA

NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232

G

cAMP responsive element binding protein 1

multiple interactions
decreases expression

EXP

[Fluoxetine co-treated with Methylphenidate] results in increased expression of CREB1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of CREB1 protein
Methylphenidate results in decreased expression of CREB1 mRNA

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

D-2-hydroxyglutarate dehydrogenase

decreases expression

ISO

Methylphenidate results in decreased expression of D2HGDH mRNA

NCBI chr 9:101,796,287...101,815,727
Ensembl chr 9:101,797,895...101,815,727

G

DAB adaptor protein 2

increases expression

ISO

Methylphenidate results in increased expression of DAB2 mRNA

NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888

G

death-associated protein kinase 3

decreases expression

ISO

Methylphenidate results in decreased expression of DAPK3 mRNA

NCBI chr 7:9,174,903...9,183,272
Ensembl chr 7:9,174,904...9,183,272

G

DEAH-box helicase 35

decreases expression

ISO

Methylphenidate results in decreased expression of DHX35 mRNA

NCBI chr 3:167,869,971...167,927,300
Ensembl chr 3:167,870,055...167,927,300

G

dopamine receptor D1

multiple interactions

EXP

[SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Methylphenidate

NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,545,111...10,567,166

G

dopamine receptor D2

multiple interactions
decreases expression
affects expression

EXP
ISO

[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Methylphenidate
Methylphenidate results in decreased expression of DRD2 mRNA
Methylphenidate affects the expression of DRD2 protein

PMID:11454915 PMID:17599397 PMID:22470460 PMID:33647392

NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:58,605,403...58,669,339

G

dopamine receptor D4

affects response to substance

ISO

DRD4 promoter mutant form affects the susceptibility to Methylphenidate

NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:205,826,049...205,830,458

G

early growth response 1

multiple interactions
increases expression

EXP

[Fluoxetine co-treated with Methylphenidate] results in increased expression of EGR1 mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of EGR1 mRNA]; Methylphenidate promotes the reaction [Amphetamine results in increased expression of EGR1 mRNA]; SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of EGR1 mRNA]

PMID:16549270 PMID:19931852 PMID:20020108 PMID:21753012

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

ectonucleoside triphosphate diphosphohydrolase 5

decreases expression

ISO

Methylphenidate results in decreased expression of ENTPD5 mRNA

NCBI chr 6:109,750,210...109,786,376
Ensembl chr 6:109,753,204...109,786,495

G

erythrocyte membrane protein band 4.1-like 1

decreases expression

ISO

Methylphenidate results in decreased expression of EPB41L1 mRNA

NCBI chr 3:165,389,295...165,512,821
Ensembl chr 3:165,389,293...165,510,498

G

EPH receptor A10

decreases expression

ISO

Methylphenidate results in decreased expression of EPHA10 mRNA

NCBI chr 5:142,424,260...142,460,305
Ensembl chr 5:142,424,296...142,460,305

G

exo/endonuclease G

decreases expression

ISO

Methylphenidate results in decreased expression of EXOG mRNA

NCBI chr 8:128,062,688...128,082,529
Ensembl chr 8:128,059,126...128,083,460

G

fibronectin type III and ankyrin repeat domains 1

decreases expression

ISO

Methylphenidate results in decreased expression of FANK1 mRNA

NCBI chr 1:198,007,496...198,114,790
Ensembl chr 1:198,007,547...198,115,561

G

Fc gamma receptor 2B

increases expression

ISO

Methylphenidate results in increased expression of FCGR2B mRNA

NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517

G

fibroblast growth factor 14

increases expression

EXP

Methylphenidate results in increased expression of FGF14 mRNA

NCBI chr15:107,442,800...108,086,486
Ensembl chr15:107,451,634...108,085,808

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
decreases expression

ISO
EXP

[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]
Methylphenidate results in increased expression of FOS mRNA
[Fluoxetine co-treated with Methylphenidate] results in increased expression of FOS mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of FOS mRNA]
Methylphenidate results in increased expression of FOS protein
Methylphenidate results in decreased expression of FOS protein
SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein]
Methylphenidate results in increased expression of FOS mRNA; Methylphenidate results in increased expression of FOS protein

PMID:12112414 PMID:12699766 PMID:15916815 PMID:19931852 PMID:21753012

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

EXP

Methylphenidate results in increased expression of FOSB protein

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

polypeptide N-acetylgalactosaminyltransferase 10

decreases expression

ISO

Methylphenidate results in decreased expression of GALNT10 mRNA

NCBI chr10:42,321,691...42,468,087
Ensembl chr10:42,322,161...42,468,087

G

GTP cyclohydrolase 1

decreases expression

ISO

Methylphenidate results in decreased expression of GCH1 mRNA

NCBI chr15:22,884,006...22,917,412
Ensembl chr15:22,884,006...22,917,412

G

glial cell derived neurotrophic factor

decreases expression

ISO

Methylphenidate results in decreased expression of GDNF mRNA

NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240

G

GH3 domain containing

decreases expression

ISO

Methylphenidate results in decreased expression of GHDC mRNA

NCBI chr10:86,193,920...86,198,141
Ensembl chr10:86,193,929...86,198,141

G

gap junction protein, beta 6

increases expression

EXP

Methylphenidate results in increased expression of GJB6 mRNA

NCBI chr15:35,400,147...35,410,649
Ensembl chr15:35,398,770...35,410,849

G

glutamate ionotropic receptor kainate type subunit 2

increases expression

EXP

Methylphenidate results in increased expression of GRIK2 mRNA

NCBI chr20:53,717,564...54,415,283
Ensembl chr20:53,716,090...54,415,202

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression

ISO

Methylphenidate results in decreased expression of GRIK3 mRNA

NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873

G

glutathione-disulfide reductase

decreases activity

ISO

Methylphenidate results in decreased activity of GSR protein

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

guanylate cyclase 2C

decreases expression

ISO

Methylphenidate results in decreased expression of GUCY2C mRNA

NCBI chr 4:171,299,715...171,380,296
Ensembl chr 4:171,299,740...171,380,296

G

HMG-box transcription factor 1

decreases expression

ISO

Methylphenidate results in decreased expression of HBP1 mRNA

NCBI chr 6:54,257,118...54,283,373
Ensembl chr 6:54,256,864...54,283,366

G

high mobility group box 1

increases expression

EXP

Methylphenidate results in increased expression of HMGB1 mRNA

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

hyaluronan-mediated motility receptor

increases expression

EXP

Methylphenidate results in increased expression of HMMR mRNA

NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390

G

heme oxygenase 1

decreases expression

ISO

Methylphenidate results in decreased expression of HMOX1 protein

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

homer scaffold protein 1

increases expression
multiple interactions

EXP

Methylphenidate results in increased expression of HOMER1 mRNA
SCH 23390 inhibits the reaction [Methylphenidate results in increased expression of HOMER1 mRNA]

PMID:16549270 PMID:17105903

NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:26,278,105...26,381,657

G

heat shock protein family B (small) member 6

decreases expression

ISO

Methylphenidate results in decreased expression of HSPB6 mRNA

NCBI chr 1:94,934,372...94,936,516
Ensembl chr 1:94,933,543...94,936,512

G

5-hydroxytryptamine receptor 1A

decreases expression

EXP

Methylphenidate decreases expression of Htr1a mRNA in the nucleus accumbens

RGD

NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760

G

5-hydroxytryptamine receptor 7

increases expression

EXP

Methylphenidate results in increased expression of HTR7 mRNA

NCBI chr 1:243,049,064...243,173,636
Ensembl chr 1:243,049,081...243,173,230

G

interleukin 1 beta

increases expression

EXP

Methylphenidate results in increased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

increases expression

ISO
EXP

Methylphenidate results in increased expression of IL6 mRNA

PMID:22470460 PMID:32746681

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

inositol hexakisphosphate kinase 1

increases expression

ISO

Methylphenidate results in increased expression of IP6K1 mRNA

NCBI chr 8:117,594,177...117,613,266
Ensembl chr 8:117,594,317...117,613,274

G

integrin subunit alpha 6

increases expression

EXP

Methylphenidate results in increased expression of ITGA6 mRNA

NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076

G

inositol 1,4,5-trisphosphate receptor, type 2

increases expression

EXP

Methylphenidate results in increased expression of ITPR2 mRNA

NCBI chr 4:180,759,325...181,165,361
Ensembl chr 4:180,760,442...181,164,763

G

Janus kinase 1

increases phosphorylation

ISO

Methylphenidate results in increased phosphorylation of JAK1 protein

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

Janus kinase 3

decreases expression

ISO

Methylphenidate results in decreased expression of JAK3 mRNA

NCBI chr16:18,418,807...18,432,515
Ensembl chr16:18,420,415...18,433,222

G

potassium two pore domain channel subfamily K member 15

increases expression

EXP

Methylphenidate results in increased expression of KCNK15 mRNA

NCBI chr 3:172,934,659...172,940,877
Ensembl chr 3:172,934,544...172,940,877

G

potassium two pore domain channel subfamily K member 3

increases expression

EXP

Methylphenidate results in increased expression of KCNK3 mRNA

NCBI chr 6:31,483,129...31,519,061
Ensembl chr 6:31,483,140...31,519,061

G

kinesin family member C3

decreases expression

ISO

Methylphenidate results in decreased expression of KIFC3 mRNA

NCBI chr19:9,831,159...9,926,405
Ensembl chr19:9,831,159...9,926,405

G

ladinin 1

decreases expression

ISO

Methylphenidate results in decreased expression of LAD1 mRNA

NCBI chr13:49,801,347...49,815,709
Ensembl chr13:49,800,472...49,815,709

G

laminin subunit alpha 3

decreases expression

ISO

Methylphenidate results in decreased expression of LAMA3 mRNA

NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449

G

laminin subunit beta 1

increases expression

EXP

Methylphenidate results in increased expression of LAMB1 mRNA

NCBI chr 6:53,562,849...53,630,118
Ensembl chr 6:53,563,073...53,630,760

G

lysosomal-associated membrane protein 2

increases expression

EXP

Methylphenidate results in increased expression of LAMP2 mRNA

NCBI chr X:122,038,734...122,087,745
Ensembl chr X:121,922,187...122,087,675

G

LARGE xylosyl- and glucuronyltransferase 1

decreases expression

ISO

Methylphenidate results in decreased expression of LARGE1 mRNA

NCBI chr19:11,609,004...12,057,174
Ensembl chr19:11,609,004...12,054,707

G

LIM and SH3 protein 1

increases expression

ISO

Methylphenidate results in increased expression of LASP1 mRNA

NCBI chr10:83,290,820...83,331,989
Ensembl chr10:83,290,865...83,331,988

G

galectin 3 binding protein

decreases expression

ISO

Methylphenidate results in decreased expression of LGALS3BP mRNA

NCBI chr10:104,118,510...104,127,848
Ensembl chr10:104,118,510...104,127,848

G

LHFPL tetraspan subfamily member 5

decreases expression

ISO

Methylphenidate results in decreased expression of LHFPL5 mRNA

NCBI chr20:6,634,058...6,644,264
Ensembl chr20:6,633,979...6,644,657

G

leucine rich repeat containing 27

decreases expression

ISO

Methylphenidate results in decreased expression of LRRC27 mRNA

NCBI chr 1:203,433,463...203,464,683
Ensembl chr 1:203,434,355...203,464,676

G

microtubule-associated protein 1 light chain 3 beta

decreases expression
increases expression

ISO
EXP

Methylphenidate results in decreased expression of MAP1LC3B mRNA
Methylphenidate results in increased expression of MAP1LC3B protein
Methylphenidate results in increased expression of MAP1LC3B mRNA

PMID:22470460 PMID:32746681 PMID:32748667

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

decreases expression
multiple interactions

EXP

Methylphenidate results in decreased expression of MAPK1 mRNA
[Fluoxetine co-treated with Methylphenidate] results in increased expression of MAPK1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen-activated protein kinase 8

increases expression

ISO

Methylphenidate results in increased expression of MAPK8 mRNA

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

modulator of VRAC current 1

decreases expression

ISO

Methylphenidate results in decreased expression of MLC1 mRNA

NCBI chr 7:121,926,356...121,949,484
Ensembl chr 7:121,926,356...121,946,698

G

matrix metallopeptidase 14

increases expression

EXP

Methylphenidate results in increased expression of MMP14 mRNA

NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893

G

MORN repeat containing 2

decreases expression

ISO

Methylphenidate results in decreased expression of MORN2 mRNA

NCBI chr 6:20,471,036...20,477,520

G

MAGUK p55 scaffold protein 3

increases expression

EXP

Methylphenidate results in increased expression of MPP3 mRNA

NCBI chr10:87,445,905...87,475,461
Ensembl chr10:87,445,905...87,474,811

G

mechanistic target of rapamycin kinase

multiple interactions
increases expression
affects expression

EXP

[Fluoxetine co-treated with Methylphenidate] results in increased expression of MTOR mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MTOR protein
Methylphenidate results in increased expression of MTOR mRNA
Methylphenidate affects the expression of MTOR mRNA

PMID:21753012 PMID:32746681

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

major vault protein

decreases expression

ISO

Methylphenidate results in decreased expression of MVP mRNA

NCBI chr 1:191,025,259...191,052,866
Ensembl chr 1:191,025,268...191,052,873

G

nucleic acid binding protein 1

increases expression

ISO

Methylphenidate results in increased expression of NABP1 mRNA

NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052

G

NAC alpha domain containing

decreases expression

ISO

Methylphenidate results in decreased expression of NACAD mRNA

NCBI chr14:85,679,215...85,688,742
Ensembl chr14:85,679,215...85,688,147

G

nuclear receptor co-repressor 2

decreases expression

ISO

Methylphenidate results in decreased expression of NCOR2 mRNA

NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612

G

neuropilin and tolloid like 2

increases expression

ISO

Methylphenidate results in increased expression of NETO2 mRNA

NCBI chr19:37,517,518...37,588,961
Ensembl chr19:37,517,587...37,591,413

G

nucleolar protein 3

decreases expression

ISO

Methylphenidate results in decreased expression of NOL3 mRNA

NCBI chr19:50,066,493...50,068,175
Ensembl chr19:50,063,986...50,068,722

G

NADPH oxidase 4

increases expression

ISO

Methylphenidate results in increased expression of NOX4 protein

NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483

G

NOP2/Sun RNA methyltransferase 4

increases expression

ISO

Methylphenidate results in increased expression of NSUN4 mRNA

NCBI chr 5:134,749,024...134,773,630
Ensembl chr 5:134,749,024...134,775,401

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

ISO

[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [Methylphenidate inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]

NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,564,570...5,874,628

G

poly (ADP-ribose) polymerase family, member 3

increases expression

ISO

Methylphenidate results in increased expression of PARP3 mRNA

NCBI chr 8:115,989,721...115,995,822
Ensembl chr 8:115,987,176...115,995,472

G

platelet endothelial aggregation receptor 1

increases expression

ISO

Methylphenidate results in increased expression of PEAR1 mRNA

NCBI chr 2:175,504,184...175,531,969
Ensembl chr 2:175,505,550...175,525,322

G

plasmanylethanolamine desaturase 1

decreases expression

ISO

Methylphenidate results in decreased expression of PEDS1 mRNA

NCBI chr 3:176,769,111...176,788,278

G

phosphatidylserine decarboxylase

decreases expression

ISO

Methylphenidate results in decreased expression of PISD mRNA

NCBI chr14:82,166,401...82,215,479
Ensembl chr14:82,166,412...82,215,913

G

protein kinase N1

decreases expression

ISO

Methylphenidate results in decreased expression of PKN1 mRNA

NCBI chr19:41,346,855...41,374,832
Ensembl chr19:41,346,860...41,378,395

G

PNMA family member 8B

increases expression

ISO

Methylphenidate results in increased expression of PNMA8B mRNA

NCBI chr 1:86,749,840...86,754,605
Ensembl chr 1:86,748,610...86,767,756

G

protein kinase cGMP-dependent 2

increases expression

ISO

Methylphenidate results in increased expression of PRKG2 mRNA

NCBI chr14:10,864,020...10,972,617
Ensembl chr14:10,864,186...10,972,614

G

prolactin receptor

decreases expression

ISO

Methylphenidate results in decreased expression of PRLR mRNA

NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:60,861,658...61,051,882

G

pre-mRNA processing factor 39

increases expression

ISO

Methylphenidate results in increased expression of PRPF39 mRNA

NCBI chr 6:88,825,227...88,851,342
Ensembl chr 6:88,825,243...88,851,341

G

phosphatidylserine synthase 2

decreases expression

ISO

Methylphenidate results in decreased expression of PTDSS2 mRNA

NCBI chr 1:205,671,024...205,695,556
Ensembl chr 1:205,671,041...205,695,553

G

protein tyrosine phosphatase, non-receptor type 21

increases expression

ISO

Methylphenidate results in increased expression of PTPN21 mRNA

NCBI chr 6:123,662,783...123,727,809
Ensembl chr 6:123,662,783...123,727,809

G

pseudouridine synthase 7 like

decreases expression

ISO

Methylphenidate results in decreased expression of PUS7L mRNA

NCBI chr 7:127,538,785...127,561,936
Ensembl chr 7:127,538,558...127,561,798

G

RAB13, member RAS oncogene family

increases expression

EXP

Methylphenidate results in increased expression of RAB13 mRNA

NCBI chr 2:177,972,535...177,977,679
Ensembl chr 2:177,972,372...177,977,684

G

RAB38, member RAS oncogene family

increases expression

ISO

Methylphenidate results in increased expression of RAB38 mRNA

NCBI chr 1:151,595,153...151,675,492
Ensembl chr 1:151,595,078...151,675,493

G

Rac GTPase-activating protein 1

decreases expression

ISO

Methylphenidate results in decreased expression of RACGAP1 mRNA

NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:132,620,595...132,659,738

G

RNA binding fox-1 homolog 1

increases expression

ISO

Methylphenidate results in increased expression of RBFOX1 mRNA

NCBI chr10:8,658,809...10,754,648
Ensembl chr10:8,658,809...10,754,706

G

regulator of chromosome condensation 2

decreases expression

ISO

Methylphenidate results in decreased expression of RCC2 mRNA

NCBI chr 5:158,277,476...158,300,294
Ensembl chr 5:158,277,476...158,300,294

G

ret proto-oncogene

decreases expression

ISO

Methylphenidate results in decreased expression of RET mRNA

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

repulsive guidance molecule BMP co-receptor a

decreases expression

ISO

Methylphenidate results in decreased expression of RGMA mRNA

NCBI chr 1:136,538,782...136,582,763
Ensembl chr 1:136,538,759...136,582,763

G

regulator of G-protein signaling 20

decreases expression

ISO

Methylphenidate results in decreased expression of RGS20 mRNA

NCBI chr 5:19,282,249...19,412,122
Ensembl chr 5:19,282,153...19,413,286

G

rhomboid domain containing 2

decreases expression

ISO

Methylphenidate results in decreased expression of RHBDD2 mRNA

NCBI chr12:26,680,206...26,690,926
Ensembl chr12:26,680,969...26,691,080

G

syndecan 3

decreases expression

ISO

Methylphenidate results in decreased expression of SDC3 mRNA

NCBI chr 5:148,249,792...148,282,524
Ensembl chr 5:148,271,842...148,280,614

G

SH3 and multiple ankyrin repeat domains 2

increases expression

EXP

Methylphenidate results in increased expression of SHANK2 mRNA

NCBI chr 1:208,575,144...209,020,300
Ensembl chr 1:208,598,772...209,018,736

G

sialic acid acetylesterase

decreases expression

ISO

Methylphenidate results in decreased expression of SIAE mRNA

NCBI chr 8:45,507,465...45,542,740
Ensembl chr 8:45,507,326...45,542,740

G

solute carrier family 10, member 4

decreases expression

ISO

Methylphenidate results in decreased expression of SLC10A4 mRNA

NCBI chr14:35,552,170...35,557,884
Ensembl chr14:35,552,170...35,557,884

G

solute carrier family 18 member A2

decreases expression
decreases activity

ISO

Methylphenidate results in decreased expression of SLC18A2 mRNA
Methylphenidate results in decreased activity of SLC18A2 protein

PMID:22470460 PMID:33378168

NCBI chr 1:268,399,815...268,435,229
Ensembl chr 1:268,400,016...268,435,231

G

solute carrier family 2 member 12

increases expression

ISO

Methylphenidate results in increased expression of SLC2A12 mRNA

NCBI chr 1:24,623,558...24,683,577
Ensembl chr 1:24,589,707...24,694,290

G

solute carrier family 6 member 3

multiple interactions
decreases expression
increases response to substance
affects response to substance

ISO

[Methylphenidate co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]
Methylphenidate results in decreased expression of SLC6A3 mRNA
Methylphenidate results in decreased expression of SLC6A3 protein
SLC6A3 protein results in increased susceptibility to Methylphenidate
SLC6A3 protein affects the reaction [Methylphenidate results in increased expression of FOS protein]
SLC6A3 3' UTR polymorphism affects the susceptibility to Methylphenidate; SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate

PMID:12112414 PMID:12699766 PMID:15059031 PMID:16139732 PMID:17234900 More...

NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:31,537,990...31,578,962

G

synaptosome associated protein 25

affects response to substance

ISO

SNAP25 gene polymorphism affects the susceptibility to Methylphenidate

NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448

G

synuclein, alpha interacting protein

increases expression

ISO

Methylphenidate results in increased expression of SNCAIP mRNA

NCBI chr18:48,402,164...48,542,246
Ensembl chr18:48,404,531...48,574,002

G

synuclein, gamma

decreases expression

ISO

Methylphenidate results in decreased expression of SNCG mRNA

NCBI chr16:9,706,765...9,712,072
Ensembl chr16:9,706,753...9,712,076

G

sorting nexin 22

decreases expression

ISO

Methylphenidate results in decreased expression of SNX22 mRNA

NCBI chr 8:75,503,297...75,509,271
Ensembl chr 8:75,504,282...75,507,939

G

sortilin-related VPS10 domain containing receptor 3

decreases expression

ISO

Methylphenidate results in decreased expression of SORCS3 mRNA

NCBI chr 1:257,040,442...257,675,259
Ensembl chr 1:257,040,473...257,675,259

G

SRY-box transcription factor 11

increases expression

ISO

Methylphenidate results in increased expression of SOX11 mRNA

NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691

G

signal transducer and activator of transcription 1

increases phosphorylation

ISO

Methylphenidate results in increased phosphorylation of STAT1 protein

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 5A

decreases expression

ISO

Methylphenidate results in decreased expression of STAT5A mRNA

NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184

G

storkhead box 2

increases expression

ISO

Methylphenidate results in increased expression of STOX2 mRNA

NCBI chr16:51,580,855...51,819,909
Ensembl chr16:51,580,798...51,815,209

G

SDS3 homolog, SIN3A corepressor complex component

decreases expression

ISO

Methylphenidate results in decreased expression of SUDS3 mRNA

NCBI chr12:45,137,964...45,160,413
Ensembl chr12:45,138,400...45,160,411

G

trace-amine-associated receptor 1

multiple interactions

ISO

Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]

NCBI chr 1:23,336,978...23,337,976
Ensembl chr 1:23,335,165...23,353,981

G

transforming growth factor, beta 3

increases expression

EXP

Methylphenidate results in increased expression of TGFB3 mRNA

NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946

G

tyrosine hydroxylase

decreases expression

ISO

Methylphenidate results in decreased expression of TH mRNA

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

G

TIMP metallopeptidase inhibitor 2

increases expression

EXP

Methylphenidate results in increased expression of TIMP2 mRNA

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214

G

TIMP metallopeptidase inhibitor 3

increases expression

EXP

Methylphenidate results in increased expression of TIMP3 mRNA

NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:19,409,631...19,459,547

G

transmembrane protein 185B

decreases expression

ISO

Methylphenidate results in decreased expression of TMEM185B mRNA

NCBI chr13:33,200,329...33,203,660
Ensembl chr13:33,198,929...33,204,091

G

transmembrane protein 30A

decreases expression

ISO

Methylphenidate results in decreased expression of TMEM30A mRNA

NCBI chr 8:89,608,975...89,637,421
Ensembl chr 8:89,608,975...89,633,291

G

tumor necrosis factor

increases expression

ISO

Methylphenidate results in increased expression of TNF mRNA

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor-associated factor 5

decreases expression

ISO

Methylphenidate results in decreased expression of TRAF5 mRNA

NCBI chr13:106,100,921...106,149,724
Ensembl chr13:106,103,291...106,149,707

G

tripartite motif-containing 25

increases expression

ISO

Methylphenidate results in increased expression of TRIM25 mRNA

NCBI chr10:74,310,024...74,328,473
Ensembl chr10:74,310,022...74,331,716

G

tetraspanin 17

decreases expression

ISO

Methylphenidate results in decreased expression of TSPAN17 mRNA

NCBI chr17:9,824,353...9,831,985
Ensembl chr17:9,823,990...9,831,974

G

transcription termination factor 1

increases expression

ISO

Methylphenidate results in increased expression of TTF1 mRNA

NCBI chr 3:32,782,544...32,807,202
Ensembl chr 3:32,782,308...32,807,201

G

twisted gastrulation BMP signaling modulator 1

decreases expression

ISO

Methylphenidate results in decreased expression of TWSG1 mRNA

NCBI chr 9:112,979,972...113,014,315
Ensembl chr 9:112,979,972...113,014,315

G

ubiquitin protein ligase E3D

decreases expression

ISO

Methylphenidate results in decreased expression of UBE3D mRNA

NCBI chr 8:96,125,609...96,293,122
Ensembl chr 8:95,882,167...96,293,078

G

UBX domain protein 10

decreases expression

ISO

Methylphenidate results in decreased expression of UBXN10 mRNA

NCBI chr 5:156,237,041...156,242,877
Ensembl chr 5:156,216,565...156,243,741

G

uridine-cytidine kinase 2

decreases expression

ISO

Methylphenidate results in decreased expression of UCK2 mRNA

NCBI chr13:81,913,732...81,971,036
Ensembl chr13:81,916,818...81,971,091

G

vasohibin 1

increases expression

ISO

Methylphenidate results in increased expression of VASH1 mRNA

NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:112,060,086...112,076,689

G

tryptophanyl tRNA synthetase 2 (mitochondrial)

decreases expression

ISO

Methylphenidate results in decreased expression of WARS2 mRNA

NCBI chr 2:189,150,322...189,233,606
Ensembl chr 2:189,145,371...189,232,970

G

ZFP14 zinc finger protein

decreases expression

ISO

Methylphenidate results in decreased expression of ZFP14 mRNA

NCBI chr 1:94,396,055...94,413,338
Ensembl chr 1:94,396,057...94,413,534

Pilsicainide hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

ISO

pilsicainide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
pilsicainide results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases activity

EXP

tiagabine results in decreased activity of AADAT protein

NCBI chr16:34,520,236...34,566,388
Ensembl chr16:34,520,238...34,566,540

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression

EXP

Amino Acids, Peptides, and Proteins inhibits the reaction [tiagabine results in increased expression of ABCB1 protein]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

increases expression

EXP

tiagabine results in increased expression of ABCC1 protein

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 2

increases expression

EXP

tiagabine results in increased expression of ABCC2 protein

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

ISO

tiagabine results in decreased activity of CYP19A1 protein

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

kynurenine aminotransferase 1

decreases activity

EXP

tiagabine results in decreased activity of KYAT1 protein

NCBI chr 3:33,857,407...33,891,153
Ensembl chr 3:33,857,743...33,890,642

G

solute carrier family 6 member 1

decreases activity

ISO

tiagabine results in decreased activity of SLC6A1 protein

NCBI chr 4:149,004,447...149,037,840
Ensembl chr 4:149,004,635...149,037,839

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20862
role	20820
application	20621
NMR chemical shift reference compound	18453
ammonia	18261
organic amino compound	18261
amino acid	16340
non-proteinogenic amino acid	4058
beta-amino acid	231
(-)-Dioxibrassinin	0
(2R,3R,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2R,3S)-3-Phenylisoserine hydrochloride	0
(2R,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2S,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2S,3S,4S)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2S,3S,6R)-3-[[3-Amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid	0
(3R)-3,6-diaminohexanoic acid	0
(3R)-3-Amino-3-(5-hydroxy-2-pyridinyl)propanoic acid	0
(3R)-3-amino-4-hydroxybutanoic acid	0
(3S)-3,6-diaminohexanoic acid	0
(3S)-3,7-diaminoheptanoic acid	0
(3S)-3-Amino-4-(1H-indol-3-yl)butanoic acid	0
(3S)-3-Amino-4-phenylbutanoic acid	0
(3S)-3-Azaniumyl-3-(4-hydroxyphenyl)propanoate	0
(3S)-3-\{[(3S)-3-Aminobutanoyl]amino\}-5-methylhexanoic acid	0
(3S,5S)-3,5-diaminohexanoic acid	0
(4E,6E)-3-(4-Formylanilino)-8-hydroxyocta-4,6-dienoic acid	0
(5Z)-3-aminonon-5-enoic acid	0
(5Z)-Bripiodionen	0
(R)-3-Amino-3-(4-hydroxy-phenyl)-propionic acid	0
(R)-3-Amino-4-(4-hydroxyphenyl)butanoic acid	0
(R)-3-Amino-4-phenylbutanoic acid	0
(S)-3-Amino-5-methylhexanoic acid	0
(S)-3-aminoisobutyric acid	0
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3-piperidin-1-ylpropanoyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(pyridin-4-ylmethyl)acetamide	0
2-[[(3-amino-4-carbamoyl-5-cyclohexylimino-2H-thiophen-2-yl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester	0
2-chloro-N-[3-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-3-oxopropyl]benzamide	0
2-phenylpiperidine-2-acetamide	0
3,7-Diaminoheptanoic Acid	0
3-(4-Chloroanilino)propanoic acid	0
3-Amino-4-(1H-indol-3-yl)butanoic Acid	0
3-Amino-4-(4-hydroxyphenyl)butyric Acid	0
3-Amino-5-methylhexanoic acid	0
3-Amino-5-methylsulfanylpentanoic acid	0
3-Aminocaproic acid	0
3-Aminopentanoic acid	0
3-[(4-methoxyphenyl)sulfonylamino]-N-(phenylmethyl)propanamide	0
3-[4-[2-(2-fluorophenyl)ethylamino]-3-nitrophenyl]-3-[[2-(1-naphthalenyl)-1-oxoethyl]amino]propanamide	0
3-[[(5-bromo-3-pyridinyl)-oxomethyl]amino]propanoic acid	0
3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid	0
3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide	3
3-[cyclopropylmethyl(propyl)amino]-N-(3,5-dimethoxyphenyl)propanamide	0
3-acetamido-N-[4-(4-methylsulfonylphenyl)-2-thiazolyl]-3-phenyl-N-prop-2-enylpropanamide	0
3-amino-3-(4-hydroxyphenyl)propanoic acid	0
3-amino-3-phenylpropanoic acid +	0
3-amino-4-(1,3-benzothiazol-2-yl)-N-(3-chloro-2-methylphenyl)-5-phenylimino-2H-thiophene-2-carboxamide	0
3-amino-N-(trans-3-carbamoyloxirane-2-carbonyl)-L-alanine	0
3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide	0
3-amino-N2-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)imino-2H-thiophene-2,4-dicarboxamide	0
3-aminoadipic acid +	0
3-aminoalanine +	0
3-aminobutanoic acid +	0
3-aminoisobutyric acid +	0
3-aminooctanoic acid	0
3-epi-deoxynegamycin	0
3-thioureidopropionic acid	0
3R-Aminononanoic acid	0
3S-aminodecanoic acid	0
4-(4-methylphenyl)-2-[[3-(4-morpholinyl)-1-oxopropyl]amino]-3-thiophenecarboxylic acid ethyl ester	0
4-Aminobenzoyl-(beta)-alanine	0
4-[3-(4-methoxyanilino)-3-oxopropyl]-1-piperazinecarboxylic acid ethyl ester	0
4-bromo-N-[3-oxo-3-(2-thiazolylamino)propyl]benzamide	0
5-[(4-methylphenyl)methylidene]-3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]-2-sulfanylidene-4-thiazolidinone	0
6-acetamido-3-aminohexanoic acid +	0
6-amino-5-cyano-4-(2-fluorophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyridine-3-carboxamide	0
6-amino-5-oxocyclohex-2-ene-1-carboxylic acid +	0
8'-Phosphoamicoumacin A	0
8'-Phosphoamicoumacin B	0
AI-77-B	0
Alchornine	0
Amicoumacin B	0
Andrimid	0
Bacilosarcin B	0
Bellenamine	0
Betamipron	0
Bilain C	0
Bis(N-pantothenylamidoethyl) disulfide	0
Bripiodionen	0
CBM 301940	0
Calcium DL-pantothenate	0
Cispentacin	0
DL-beta-Homophenylalanine	0
Demethylblasticidin S	0
Ethyl 3(R)-acetamido-3-(4-hydroxyphenyl)propanoate	0
Haenamindole	0
L-3-Aminobutyric acid	0
L-beta-Homothreonine	0
L-beta-Homotyrosine	0
L-beta-homomethionine	0
LSM-10180	0
LSM-10293	0
LSM-10415	0
LSM-10539	0
LSM-10584	0
LSM-10682	0
LSM-11427	0
LSM-11607	0
LSM-11961	0
LSM-12217	0
LSM-12542	0
LSM-13256	0
LSM-13387	0
LSM-13653	0
LSM-14141	0
LSM-14406	0
LSM-14586	0
LSM-14616	0
LSM-31117	0
LSM-9418	0
LSM-9594	0
LSM-9952	0
Leuhistin	0
Methyl 3-(4-chloroanilino)propanoate	0
Moiramide A	0
Moiramide C	0
N'-(benzenesulfonyl)-3-[5-[(4-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]propanehydrazide	0
N,N-dimethyl-beta-alanine	0
N-(2,4-dimethoxyphenyl)-3-(4-morpholinyl)propanamide	0
N-(4,5-dihydrothiazol-2-yl)-3-[5-[(3,4-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]propanamide	0
N-(4-phenylmethoxyphenyl)-3-[4-(phenylmethyl)-1-piperazinyl]propanamide	0
N-[(2-ethoxyphenyl)methyl]-3-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]propanamide	0
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[[anilino(oxo)methyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[3-[(1,3-dimethyl-2,6-dioxo-4-pyrimidinyl)methylamino]-3-oxopropyl]-3-methoxybenzamide	0
N-[3-[4-[(2-methoxyphenyl)sulfamoyl]anilino]-3-oxopropyl]-2-furancarboxamide	0
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(4S,5S)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-cyclopentyl-3-[(4-methylphenyl)sulfonylamino]propanamide	0
N-methyl-beta-alanine +	0
Negamycin	0
Obscurolide-C2	0
Obscurolide-C2 methyl ester	0
Pantothenamide	0
Peniginseng A	0
Pestalotiopamide D	0
Pilsicainide hydrochloride	1
Putreanine	0
Roseothricin (H-277)	0
SF2768 I	0
Sperabillin A	0
Spermic acid 1	0
Spermic acid 2	0
Sporovexin C	0
TAN-1057C	0
Taveuniamide A	0
Taveuniamide B	0
Taveuniamide C	0
Taveuniamide D	0
Taveuniamide E	0
Termitomycamide D	0
alpha-Fluoro-beta-alanine	0
aspartic 1-amide +	0
aspartyl adenylate beta-ketophosphonate isostere	0
beta-alanine +	60
beta-amino acid ester +	168
beta-leucine +	0
gemigliptin	0
guvacine +	0
moiramide B	0
nipecotic acid +	7
octacaine	0
phenylacetyl-beta-alanine	0
smenospongines C	0
substituted beta-amino acids	0
tiagabine	7
Path 2
Term	Annotations
CHEBI ontology	20862
subatomic particle	20860
composite particle	20860
hadron	20860
baryon	20860
nucleon	20860
atomic nucleus	20860
atom	20860
main group element atom	20781
main group molecular entity	20781
s-block molecular entity	20574
hydrogen molecular entity	20558
hydrides	19693
inorganic hydride	18602
pnictogen hydride	18589
nitrogen hydride	18502
azane	18262
ammonia	18261
organic amino compound	18261
amino acid	16340
non-proteinogenic amino acid	4058
beta-amino acid	231
(-)-Dioxibrassinin	0
(2R,3R,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2R,3S)-3-Phenylisoserine hydrochloride	0
(2R,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2S,3S,4R)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2S,3S,4S)-4-(hydroxymethyl)-1-[1-oxo-3-(1-piperidinyl)propyl]-3-phenyl-2-azetidinecarbonitrile	0
(2S,3S,6R)-3-[[3-Amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid	0
(3R)-3,6-diaminohexanoic acid	0
(3R)-3-Amino-3-(5-hydroxy-2-pyridinyl)propanoic acid	0
(3R)-3-amino-4-hydroxybutanoic acid	0
(3S)-3,6-diaminohexanoic acid	0
(3S)-3,7-diaminoheptanoic acid	0
(3S)-3-Amino-4-(1H-indol-3-yl)butanoic acid	0
(3S)-3-Amino-4-phenylbutanoic acid	0
(3S)-3-Azaniumyl-3-(4-hydroxyphenyl)propanoate	0
(3S)-3-\{[(3S)-3-Aminobutanoyl]amino\}-5-methylhexanoic acid	0
(3S,5S)-3,5-diaminohexanoic acid	0
(4E,6E)-3-(4-Formylanilino)-8-hydroxyocta-4,6-dienoic acid	0
(5Z)-3-aminonon-5-enoic acid	0
(5Z)-Bripiodionen	0
(R)-3-Amino-3-(4-hydroxy-phenyl)-propionic acid	0
(R)-3-Amino-4-(4-hydroxyphenyl)butanoic acid	0
(R)-3-Amino-4-phenylbutanoic acid	0
(S)-3-Amino-5-methylhexanoic acid	0
(S)-3-aminoisobutyric acid	0
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3-piperidin-1-ylpropanoyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(pyridin-4-ylmethyl)acetamide	0
2-[[(3-amino-4-carbamoyl-5-cyclohexylimino-2H-thiophen-2-yl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester	0
2-chloro-N-[3-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-3-oxopropyl]benzamide	0
2-phenylpiperidine-2-acetamide	0
3,7-Diaminoheptanoic Acid	0
3-(4-Chloroanilino)propanoic acid	0
3-Amino-4-(1H-indol-3-yl)butanoic Acid	0
3-Amino-4-(4-hydroxyphenyl)butyric Acid	0
3-Amino-5-methylhexanoic acid	0
3-Amino-5-methylsulfanylpentanoic acid	0
3-Aminocaproic acid	0
3-Aminopentanoic acid	0
3-[(4-methoxyphenyl)sulfonylamino]-N-(phenylmethyl)propanamide	0
3-[4-[2-(2-fluorophenyl)ethylamino]-3-nitrophenyl]-3-[[2-(1-naphthalenyl)-1-oxoethyl]amino]propanamide	0
3-[[(5-bromo-3-pyridinyl)-oxomethyl]amino]propanoic acid	0
3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid	0
3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide	3
3-[cyclopropylmethyl(propyl)amino]-N-(3,5-dimethoxyphenyl)propanamide	0
3-acetamido-N-[4-(4-methylsulfonylphenyl)-2-thiazolyl]-3-phenyl-N-prop-2-enylpropanamide	0
3-amino-3-(4-hydroxyphenyl)propanoic acid	0
3-amino-3-phenylpropanoic acid +	0
3-amino-4-(1,3-benzothiazol-2-yl)-N-(3-chloro-2-methylphenyl)-5-phenylimino-2H-thiophene-2-carboxamide	0
3-amino-N-(trans-3-carbamoyloxirane-2-carbonyl)-L-alanine	0
3-amino-N-[2-(1H-imidazol-5-yl)ethyl]propanamide	0
3-amino-N2-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)imino-2H-thiophene-2,4-dicarboxamide	0
3-aminoadipic acid +	0
3-aminoalanine +	0
3-aminobutanoic acid +	0
3-aminoisobutyric acid +	0
3-aminooctanoic acid	0
3-epi-deoxynegamycin	0
3-thioureidopropionic acid	0
3R-Aminononanoic acid	0
3S-aminodecanoic acid	0
4-(4-methylphenyl)-2-[[3-(4-morpholinyl)-1-oxopropyl]amino]-3-thiophenecarboxylic acid ethyl ester	0
4-Aminobenzoyl-(beta)-alanine	0
4-[3-(4-methoxyanilino)-3-oxopropyl]-1-piperazinecarboxylic acid ethyl ester	0
4-bromo-N-[3-oxo-3-(2-thiazolylamino)propyl]benzamide	0
5-[(4-methylphenyl)methylidene]-3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]-2-sulfanylidene-4-thiazolidinone	0
6-acetamido-3-aminohexanoic acid +	0
6-amino-5-cyano-4-(2-fluorophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyridine-3-carboxamide	0
6-amino-5-oxocyclohex-2-ene-1-carboxylic acid +	0
8'-Phosphoamicoumacin A	0
8'-Phosphoamicoumacin B	0
AI-77-B	0
Alchornine	0
Amicoumacin B	0
Andrimid	0
Bacilosarcin B	0
Bellenamine	0
Betamipron	0
Bilain C	0
Bis(N-pantothenylamidoethyl) disulfide	0
Bripiodionen	0
CBM 301940	0
Calcium DL-pantothenate	0
Cispentacin	0
DL-beta-Homophenylalanine	0
Demethylblasticidin S	0
Ethyl 3(R)-acetamido-3-(4-hydroxyphenyl)propanoate	0
Haenamindole	0
L-3-Aminobutyric acid	0
L-beta-Homothreonine	0
L-beta-Homotyrosine	0
L-beta-homomethionine	0
LSM-10180	0
LSM-10293	0
LSM-10415	0
LSM-10539	0
LSM-10584	0
LSM-10682	0
LSM-11427	0
LSM-11607	0
LSM-11961	0
LSM-12217	0
LSM-12542	0
LSM-13256	0
LSM-13387	0
LSM-13653	0
LSM-14141	0
LSM-14406	0
LSM-14586	0
LSM-14616	0
LSM-31117	0
LSM-9418	0
LSM-9594	0
LSM-9952	0
Leuhistin	0
Methyl 3-(4-chloroanilino)propanoate	0
Moiramide A	0
Moiramide C	0
N'-(benzenesulfonyl)-3-[5-[(4-methylphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]propanehydrazide	0
N,N-dimethyl-beta-alanine	0
N-(2,4-dimethoxyphenyl)-3-(4-morpholinyl)propanamide	0
N-(4,5-dihydrothiazol-2-yl)-3-[5-[(3,4-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-3-thiazolidinyl]propanamide	0
N-(4-phenylmethoxyphenyl)-3-[4-(phenylmethyl)-1-piperazinyl]propanamide	0
N-[(2-ethoxyphenyl)methyl]-3-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]propanamide	0
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[[anilino(oxo)methyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide	0
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(2-thiazolylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-3-(1-piperidinyl)propanamide	0
N-[3-[(1,3-dimethyl-2,6-dioxo-4-pyrimidinyl)methylamino]-3-oxopropyl]-3-methoxybenzamide	0
N-[3-[4-[(2-methoxyphenyl)sulfamoyl]anilino]-3-oxopropyl]-2-furancarboxamide	0
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-pent-1-ynyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(4S,5R)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-[[(4S,5S)-8-bromo-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^\{6\},2-benzoxathiazocin-5-yl]methyl]-N-methyl-3-(1-piperidinyl)propanamide	0
N-cyclopentyl-3-[(4-methylphenyl)sulfonylamino]propanamide	0
N-methyl-beta-alanine +	0
Negamycin	0
Obscurolide-C2	0
Obscurolide-C2 methyl ester	0
Pantothenamide	0
Peniginseng A	0
Pestalotiopamide D	0
Pilsicainide hydrochloride	1
Putreanine	0
Roseothricin (H-277)	0
SF2768 I	0
Sperabillin A	0
Spermic acid 1	0
Spermic acid 2	0
Sporovexin C	0
TAN-1057C	0
Taveuniamide A	0
Taveuniamide B	0
Taveuniamide C	0
Taveuniamide D	0
Taveuniamide E	0
Termitomycamide D	0
alpha-Fluoro-beta-alanine	0
aspartic 1-amide +	0
aspartyl adenylate beta-ketophosphonate isostere	0
beta-alanine +	60
beta-amino acid ester +	168
beta-leucine +	0
gemigliptin	0
guvacine +	0
moiramide B	0
nipecotic acid +	7
octacaine	0
phenylacetyl-beta-alanine	0
smenospongines C	0
substituted beta-amino acids	0
tiagabine	7

paths to the root